The WATCHMAN FLX device showed superior safety with 8.5% major bleeding at 36 months, compared to 18.1% with oral ...

The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.

Boston Scientific announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX device.

Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on BSX stock, giving a Buy rating yesterday.Don't Miss our Black ...

In a report released on November 15, David Rescott from Robert W. Baird maintained a Buy rating on Boston Scientific (BSX – Research Report), ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Boston Scientific (BSX) stock climbed 5% after a study showed its Watchman FLX device was superior to oral anti-coagulants in reducing bleeding risks following cardiac ablation.

Marlborough, Massachusetts Tuesday, November 19, 2024, 17:00 Hrs [IST] ...

Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global ...

Although some of the trial’s methodology was critiqued, the results provide fodder for shared decision-making discussions.

Abbott has reported late-breaking five-year positive data from a trial of its Amplatzer Amulet left atrial appendage (LAA) ...

At the moment, the company is developing novel therapeutic approaches for patients with underserved heart issues, such as ...